Conference Coverage

DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening

Publish date: August 27, 2022

 

AT ESC CONGRESS 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Does DTC heart drug advertising discourage lifestyle changes?
Clinician Reviews
Cholesterol levels lowering in U.S., but disparities emerge
Clinician Reviews
How much weight does my patient need to lose?
Clinician Reviews
Barcelona beckons for first hybrid ESC Congress
Clinician Reviews
‘Conservative’ USPSTF primary prevention statin guidance finalized
Clinician Reviews
NSAIDs linked to heart failure risk in diabetes
Clinician Reviews
Early menopause linked with increased risk of heart problems
Clinician Reviews
Congressman’s wife died after taking herbal remedy marketed for diabetes and weight loss
Clinician Reviews
Secondary CV prevention benefit from polypill promises global health benefit
Clinician Reviews
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
Clinician Reviews